Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | USP19 | O94966 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381419 | 0.68 | POLB (0.46) | KDM4ELMNANPC1KMT2A | |
| SCHEMBL6675403 | 0.68 | CYP3A4 (0.52) | CYP3A4CYP1A2CYP2D6ADORA2BKDM4E | |
| SCHEMBL16371569 | 0.67 | ALDH1A1 (0.35) | CYP3A4CYP1A2CYP2D6ADORA2BLMNA | |
| SCHEMBL7614386 | 0.67 | KDM4C (0.50) | CYP3A4CYP1A2CYP2D6KDM4EADORA2A | |
| SCHEMBL2086433 | 0.67 | ADORA2B (0.35) | CYP3A4CYP1A2CYP2D6ADORA2BPDE4A | |
| SCHEMBL1490959 | 0.65 | ADORA2B (0.33) | CYP3A4CYP1A2CYP2D6ADORA2BLMNA | |
| SCHEMBL9292715 | 0.65 | CYP3A4 (0.35) | CYP3A4CYP1A2CYP2D6ADORA2BKDM4E | |
| SCHEMBL9749715 | 0.65 | ADORA2B (0.37) | CYP3A4CYP1A2CYP2D6ADORA2BPDE4A | |
| SCHEMBL21527215 | 0.65 | MAPT (0.56) | LMNANPC1KMT2A | |
| SCHEMBL20417809 | 0.64 | SMN1; SMN2 (0.42) | CYP3A4CYP1A2CYP2D6KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62198671-A | — | — | None | — | — | JP | disclosed |
| US-8211920-B2 | 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090215834-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-4870176-A | ANTI-LIPOPEROXIDE, VASODILATION, ANTICOAGULANTS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-09-26 | — | — | US | disclosed |
| US-4870176-A | ANTI-LIPOPEROXIDE, VASODILATION, ANTICOAGULANTS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-09-26 | — | — | US | disclosed |
| US-4837319-A | VASODILATORS, ANTICOAGULANTS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0242957-A1 | 1-Substituted Alkyl-1, 2-Dihydro-2-Pyrazinone derivatives | TOYO JOZO KABUSHIKI KAISHA (JP) | 1987-10-28 | — | — | EP | disclosed |
| JP-S62198671-A | 1-SUBSTITUTED ALKYL 1, 2-DIHYDRO-2-PYRAZINONE DERIVATIVE | TOYO JOZO CO LTD | 1987-09-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215834-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | CYP3A4 727/4885CYP1A2 467/4885CYP2D6 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.